Recent News
Read ArticleDay two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2.
Biologic Class Determines PsA Risk in Psoriasis
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
Read Article
A biomarker for CV disease in RA?
Anti-CXCR3 antibodies asso w/ atherosclerosis
Confirmed in a validation cohort
Adding Ab profile to the mSCORE increases
AUC from 0.6 to 0.9
Sens from 30 to 69%
How does it compare with other ways of detecting atherosclerosis?
#POS0899 https://t.co/O7bsLrVyzo
Links:
Aurelie Najm @AurelieRheumo ( View Tweet)
How to treat #RA-#ILD
Similar to #IPF
Occurs older men esp
Smoking risk
Vaccines
Etc
Philippe Dieude
#HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF
Janet Pope @Janetbirdope ( View Tweet)
Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/uTxEJqbDBm
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Controversial
#Rheumatoid #arthritis disease activity
May not affect #ILD
BUT affects #mortality
level evidence +/-
PHillippe Dieude said
#Rx from RCTs
#IS
Ex #rituximab
#antifibrotics
#nintedanib
#nerandomilast
HOw to Treat RA-ILD June 5
#EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8
Links:
Janet Pope @Janetbirdope ( View Tweet)
Which b/tsDMARDs are NOT effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/hqfLAYeri3
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
Key messages in the tx of ax/p-SpA:
>csDMARDs only effective in pSpA
>consider individualized treatment for bDMARDs and JAKis
>Cycling TNFi equally effective to switching
@RheumNow #EULAR2026 https://t.co/oeO3BxmYYo
sheila @RHEUMarampa ( View Tweet)
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Dr. John Cush @RheumNow ( View Tweet)
Which b/tsDMARDs are effective in #axSpA?
Check out the latest update of the treatment heatmap 🔥
By Astrid van Tubergen
At axial and peripheral SpA at a crossroads session
#EULAR2026
@RheumNow https://t.co/8mj24lAOTk
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
What b/ts DMARDs are effective and not effective in axSpA?
Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA.
@RheumNow #EULAR2026 https://t.co/5udGPB1Hrr
Links:
sheila @RHEUMarampa ( View Tweet)
What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis?
👉 DAPSA44
✔️Good construct validity
✔️ High discriminatory capacity
From the ASAS-Sparadise study
#EULAR2026
@RheumNow https://t.co/Jbdvpn95jE
Nelly ZIADE 🍀 @Nellziade ( View Tweet)
#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming
➡️esp if multi drug failure already
By Hector Chinoy #WIN #IIM June5
Excellent #CAR-T review
should re think of
Total immune reset in many #SARD PTS is unlikely
EULAR2026 @RheumNow https://t.co/eqKzxzqa0z
Links:
Janet Pope @Janetbirdope ( View Tweet)
Using AI to integrate EHR, SDOH , psychological data - can help finding psychosocial risk factors.
Complex cases can be diagnosed using solutions (iceberg health) like this. #EULAR2026 @rheumnow https://t.co/t4keRbpkrx
Links:
Bella Mehta @bella_mehta ( View Tweet)
Not just ticking boxes!
Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA
What’s new?
Providing a stem so criteria will be applied only if w/SpA dx, not just imaging
MRI:active inflamm + structural lesions
Some SpA features omitted
@RheumNow #EULAR2026 https://t.co/NCV0EFvjYa
Links:
sheila @RHEUMarampa ( View Tweet)
Can we have an effective, comprehensive score for
#SLE #arthritis?
#SLEDAI has a problem
SJC>2 scores dames as ex #SJC=12
Meet
#LAMBDA
An attempt to improve a true positive #MSK OUTCOME in #lupus
Needs validation esp in pts over time
#EULAR2026 @RheumNow #POS1072
@eular_org https://t.co/fr0xuVqFnM
Janet Pope @Janetbirdope ( View Tweet)
Large French nationwide cohort (n=56,591 SpA patients) showed that >6 months/year of targeted therapy exposure was associated with reduced overall cancer risk (wHR 0.86), especially for haematological malignancies (wHR 0.65). Reassuring long-term safety signal. Abstr OP0238
Antoni Chan MD (Prof) @synovialjoints ( View Tweet)
Not all #RA pts respond equally to advanced therapy. 10-variable risk model >18k US pts: low baseline disease activity, fewer comorbidities, and no prior biologics 5x more likely to achieve remission at 1yr (34% vs 7%). RWD for precision care @RheumNow #EULAR2026 POS0257
Jiha Lee @JihaRheum ( View Tweet)
Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288
Jiha Lee @JihaRheum ( View Tweet)
The axSpA classification has been revised with the 2025 ASAS SPARTAN criteria. 5 abstracts at #EULAR2026 Abstr OP0236, OP0100, OP0239, POS0190 and POS1341.
The single most important change in the 2025 criteria: MRI is now the highest-weighted variable and what counts as a https://t.co/xg4R4xRH2D
Antoni Chan MD (Prof) @synovialjoints ( View Tweet)
From the Blog
Podcasts
EULAR 2026 Daily Podcast Day 2b
Daily Recap Day 1 + 2 EULAR 2026-
EULAR 2026 Daily Podcast Day 2a
-
EULAR 2026 Daily Podcast Day 1a
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
